p16 expression in the female genital tract and its value in diagnosis

Advances in Anatomic Pathology

Volumn 13, Issue 1, 2006, Pages 8-15

  O'Neill, Ciaran J ^a   McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Diagnosis; Gynecologic neoplasms; Immunohistochemistry; p16

Indexed keywords

PROTEIN P16; PROTEIN P16INK4A; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ENDOMETRIUM CARCINOMA; FEMALE GENITAL SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; METASTASIS; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; ADENOCARCINOMA; CHEMISTRY; CLASSIFICATION; CYSTADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM TUMOR; FEMALE; FEMALE GENITAL TRACT TUMOR; GENETICS; OVARY TUMOR; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR; UTERUS CANCER; VULVA TUMOR;

ADENOCARCINOMA; CARCINOMA, SMALL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P16; GENITAL NEOPLASMS, FEMALE; GENITALIA, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; VULVAR NEOPLASMS;

EID: 33644939223     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000201828.92719.f3     Document Type: Review

References (65)

1. Sharpless NE, Chin L. The INK 4a/ARF locus and melanoma. Oncogene. 2003;22:3092-3098.
2. Soufir N, Basset-Seguin N. The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis. Bull Cancer. 2001;88:1061-1067.
3. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5:2704-2713.
4. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576:22-38.
5. Sano T, Oyama T, Kashiwabara K, et al. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int. 1998;48:580-585.
6. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, et al. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest. 1999;79:1137-1143.
7. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42-55.
8. Cohen JA, Geradts J. Loss of Rb and MTS1/CDKN2 (P16) expression in human sarcomas. Hum Pathol. 1997;28:893-898.
9. Vo QN, Geradts J, Boudreau DA, et al. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables. Hum Pathol. 2002;33:1200-1204.
10. Guenova M, Rassidakis GZ, Gorgoulis VG, et al. P16-INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status and the presence of EBV. Mod Pathol. 1999;12:1062-1071.
11. Bai M, Vlachoniklois J, Agnantis, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol. 2001;14:1105-1113.
12. Beasley MB, Lantuejoul S, Abbondanzo S, et al. The p16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol. 2003;34:136-142.
13. Levrsha MA, Fielding P, Watson S, et al. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol. 2003;200:610-619.
14. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748.
15. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
16. Keating JT, Cviko A, Reithdorf S, et al. Ki-67, cyclin E and p16 are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am J Surg Pathol. 2001;25:894-991.
17. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162:747-753.
18. Lu DW, El-Mofty S, Wang HL. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol. 2003;16:692-699.
19. Milde-Langosch K, Reithdorf S, Kraws-Poppinghaus A. Expression of cyclin-dependent kinase inhibitors p16, p21 and p27 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch. 2001;439:55-61.
20. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16 INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol. 2005;29:674-679.
21. Hu L, Guo M, He Z, et al. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol. 2005;18:267-273.
22. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol. 2004;35:689-696.
23. Dray M, Russell P, Dulrymple C, et al. p16 (INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology. 2005;37:112-124.
24. Agoff SN, Lin P, Morihara J, et al. p16 (INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki67 expression and detection of high-risk HPV types. Mod Pathol. 2003;16:665-673.
25. Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004;445:616-620.
26. Guimaraes MC, Goncalves MA, Soares P, et al. Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions. J Histochem Cytochem. 2005;53:509-516.
27. Aoyama C, Liu P, Ostrzega N, et al. Histologic and immunohistochemical characteristics of neoplastic and nonneoplastic subgroups of atypical squamous lesions of the uterine cervix. Am J Clin Pathol. 2005;123:699-705.
28. McCluggage WG, Bharucha H, Caughley LM, et al. Interobserver variation in the reporting of cervical colposcopic biopsy specimens: comparison of grading systems. J Clin Pathol. 1996;49:833-835.
29. Klaes R, Benner A, Friedrich T, et al. p16 INK 4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-1399.
30. Qiao X, Bhuiya TA, Spitzer M. Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausalwomen using Ki-67, cyclin E and p16 immunohistochemical analysis. J Low Genit Tract Dis. 2005;9:100-107.
31. Cameron RI, Maxwell P, Jenkins D, et al. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology. 2002;41:313-321.
32. McCluggage WG, Jenkins D. Immunohistochemical staining with p16 may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003;22:231-235.
33. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16 INK 4 A expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201:535-543.
34. Toki T, Zhai YL, Park JS, et al. Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix. Int J Gynecol Pathol. 2002;18:215-219.
35. Mikami Y, Kikoyawa T, Hata S, et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and 'adenoma malignum.' Mod Pathol. 2004;17:962-972.
36. Parwani AV, Smith Sehdev AE, Kurman RJ, et al. Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection and p16 expression. Hum Pathol. 2005;36:82-90.
37. Park JJ, Sun D, Quade BJ, et al. Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia? Am J Surg Pathol. 2000;24:1414-1419.
38. Negri G, Egarter-Vigl E, Kasal A, et al. p16 INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003;27:187-193.
39. Murphy N, Heffron CC, Ling B, et al. p16INK4a positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchow Arch. 2004;445:610-615.
40. Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16 and early endocervical glandular neoplasia. Hum Pathol. 2002;33:899-904.
41. Zaino RJ. The fruits of our labors: distinguishing endometrial from endocervical adenocarcinoma. Int J Gynecol Pathol. 2002;21:1-3.
42. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160-167.
43. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin and estrogen receptor aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11-15.
44. Castillon DH, Lee KR, Nucci MR, et al. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4-10.
45. Wang HL, Lu DW. Detection of human papillomavirus DNA and expression of p16, Rb and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol. 2004;28:901-908.
46. Masumoto N, Fuji T, Ishikawa M, et al. p16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol. 2003;34:778-783.
47. Bose S, Evans H, Lantzy L, et al. p16(INK4A) is a surrogate biomarker for a subset of human papilloma virus associated dysplasias of the uterine cervix as determined on the Pap smear. Diagn Cytopathol. 2005;32:21-24.
48. Nieh S, Chen SF, Chu TY, et al. Is p16(INK4A) expression more useful than human papilloma virus test to determine the outcome of atypical squamous cells of uncertain significance-categorised Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol. 2005;97:35-40.
49. Yoshida T, Fukuda T, Sano T, et al. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer. 2004;102:100-108.
50. Sahebali S, Depudyt CE, Segers K, et al. P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer. 2004;108:871-876.
51. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the Rb1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16 (INK4a) protein. Int J Gynecol Pathol. 2005;24:363-368.
52. Zhai YL, Nikaido T, Orii A, et al. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol. 1999;75:453-459.
53. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol. 2005;96:62-66.
54. Santos M, Montagut C, Mellado B, et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol. 2004;23:206-214.
55. Riethdorf S, Neffen EF, Cviko A, et al. p16 INK4A expression as biomarker for HPV16-related vulvar neoplasias. Hum Pathol. 2004;35:1477-1483.
56. Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathological study including analysis of HPV and p53 expression. Am J Surg Pathol. 2000;24:429-441.
57. Kaefner HK, Tate JE, Mc Lachlin CM, et al. Vulvar intraepithelial neoplasia. Morphological phenotype, papillomavirus DNA and coexisting invasive carcinoma. Hum Pathol. 1995;26:147-154.
58. Ruhul Quddus M, Xu C, Steinhoff MM, et al. Simplex (differentiated) type VIN: absence of p16 INK4 supports its weak association with HPV and its probable precursor role in non-HPV related vulvar squamous cancers. Histopathology. 2005;46:718-720.
59. Dong Y, Walsh MD, McGuckin MA, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer. 1997;74:57-63.
60. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281-294.
61. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, BCL2, HER-2/neu and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29:1034-1041.
62. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol. 2004;203:617-619.
63. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
64. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol. 2003;22:37-41.
65. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.